Head and Neck Squamous Cell Cancer Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting head and neck squamous cell cancer clinical trials across 3 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Nashville, Tennessee, United States, Los Angeles, California, United States, St Louis, Missouri, United States. Updated daily from ClinicalTrials.gov.


Head and Neck Squamous Cell Cancer Trials at a Glance

7 actively recruiting trials for head and neck squamous cell cancer are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 5 trials, with the heaviest enrollment activity in Nashville, Los Angeles, and St Louis. Lead sponsors running head and neck squamous cell cancer studies include EpiBiologics, Exelixis, and A2 Biotherapeutics Inc..

Browse head and neck squamous cell cancer trials by phase

Treatments under study

About Head and Neck Squamous Cell Cancer Clinical Trials

Looking for clinical trials for Head and Neck Squamous Cell Cancer? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Head and Neck Squamous Cell Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Head and Neck Squamous Cell Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Head and NeckHead and Neck Squamous Cell Carcinoma (HNSCC)Head and Neck Cancer+12 more
EpiBiologics110 enrolled6 locationsNCT07462377
Recruiting
Phase 1

Study of XB010 in Subjects With Solid Tumors

Hormone Receptor-Positive Breast CancerLocally Advanced or Metastatic Solid TumorsTriple Negative Breast Cancer(TNBC)+3 more
Exelixis396 enrolled19 locationsNCT06545331
Recruiting
Phase 1

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Head and Neck CancerSolid TumorsHNSCC+10 more
VLP Therapeutics41 enrolled1 locationNCT06736379
Recruiting
Phase 1

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793
Recruiting

Smoking cessation and effects of cigarette smoking on cure and side effects of treatment in patients with cancer in the head and neck region.

Head and Neck Squamous Cell Cancer
MADHAVI CHILKURI156 enrolled1 locationACTRN12618000165280
Recruiting
Phase 3

The effect of Taxotere, Cisplatin and 5-Fluorouracil (TPF) induction chemotherapy on intratumoral hypoxia in advanced head and neck squamous cell cancer

advanced head and neck squamous cell cancer
Peter MacCallum Cancer Centre25 enrolled1 locationACTRN12609000642280